• BioVersys AG

    BS
    aktiv
    Jetzt Bonität prüfen Zur Timeline
    Jetzt Bonität prüfenBonität prüfen
    Handelsregister-Nr.: CH-400.4.030.951-8
    Branche: Durchführung von Forschungen und Entwicklungen

    Alter der Firma

    16 Jahre

    Umsatz in CHF

    PremiumPremium

    Kapital in CHF

    5,8 Mio.

    Mitarbeiter

    PremiumPremium

    Aktive Marken

    0

    Auskünfte zu BioVersys AG

    *angezeigte Auskünfte sind Beispiele
    preview

    Bonitätsauskunft

    Einschätzung der Bonität mit einer Ampel als Risikoindikator und weiteren hilfreichen Firmeninformationen.
    Mehr erfahren
    preview

    Wirtschaftsauskunft

    Umfassende Auskunft über die wirtschaftliche Situation der Firma.
    Mehr erfahren
    preview

    Zahlungsverhalten

    Beurteilung der Zahlungsmoral aufgrund vergangener Rechnungen.
    Mehr erfahren
    preview

    Betreibungsauskunft

    Übersicht über aktuelle und vergangene Betreibungsverfahren.
    Mehr erfahren
    preview

    Beteiligungsauskunft

    Erfahren Sie, an welchen nationalen und internationalen Firmen die Aktiengesellschaft, für die Sie sich interessieren, noch beteiligt ist.
    Mehr erfahren
    preview

    Firmendossier als PDF

    Kontaktinformationen, Veränderungen, Umsatz- und Mitarbeiterzahlen, Management, Besitzverhältnisse, Beteiligungsstruktur und weitere Firmendaten.
    Jetzt kostenlos abrufen

    Über BioVersys AG

    • BioVersys AG ist in der Branche «Durchführung von Forschungen und Entwicklungen» tätig und ist aktuell aktiv. Der Sitz ist in Basel.
    • Die Firma wurde am 24.09.2008 gegründet.
    • Alle Anpassungen am Handelsregistereintrag finden Sie unter Meldungen. Die letzte Anpassung erfolgte am 11.07.2025.
    • BioVersys AG ist im Kanton BS unter der UID CHE-114.512.761 eingetragen.
    • ADVESYA AG, AlloCyte Pharmaceuticals AG, Anaveon AG sind an derselben Adresse eingetragen.

    Handelsregisterinformationen

    Quelle: SHAB

    Branche

    Durchführung von Forschungen und Entwicklungen

    Firmenzweck

    Die Gesellschaft bezweckt die Erforschung, die Entwicklung, die Herstellung, die Verwertung, den Erwerb und den Vertrieb von pharmazeutischen und diagnostischen Produkten und Technologien. Die Gesellschaft kann alle kommerziellen, vertraglichen und finanziellen Geschäfte eingehen, die geeignet sind, den Zweck der Gesellschaft zu fördern, oder sie direkt oder indirekt damit in Zusammenhang stehen. Ferner kann sie Zweigniederlassungen im In- und Ausland einrichten und sich an anderen Unternehmungen beteiligen oder sich mit diesen zusammenschliessen. Die Gesellschaft kann Grundstücke erwerben, halten und veräussern.

    Passen Sie den Firmenzweck mit wenigen Klicks an.

    Revisionsstelle

    Quelle: SHAB

    Aktive Revisionsstelle (1)
    Name Ort Seit Bis
    Ernst & Young AG
    Basel 08.07.2013

    Möchten Sie die Revisionsstelle anpassen? Klicken Sie hier.

    Frühere Revisionsstelle (1)
    Name Ort Seit Bis
    LLK Revision AG in Liquidation
    Liestal 07.04.2011 07.07.2013

    Weitere Firmennamen

    Quelle: SHAB

    Frühere und übersetzte Firmennamen

    • BioVersys Ltd
    • BioVersys GmbH
    Möchten Sie den Firmennamen aktualisieren? Klicken Sie hier.

    Zweigniederlassungen (0)

    Besitzverhältnisse

    Es liegen uns keine Angaben zu den Besitzverhältnissen vor.

    Beteiligungen

    Es liegen uns keine Angaben zu den Beteiligungen vor.

    Neueste SHAB-Meldungen: BioVersys AG

    Neueste Meldungen vom Schweizerischen Handelsamtsblatt (SHAB) sind nur in der Originalsprache des jeweiligen Handelsregisteramtes verfügbar. Alle Meldungen ansehen

    SHAB 250711/2025 - 11.07.2025
    Kategorien: Änderung im Management

    Publikationsnummer: HR02-1006382297, Handelsregister-Amt Basel-Stadt, (270)

    BioVersys AG, in Basel, CHE-114.512.761, Aktiengesellschaft (SHAB Nr. 54 vom 19.03.2025, Publ. 1006286040).

    Statutenänderung:
    27.06.2025. Die Gesellschaft hat mit Beschluss vom 27.06.2025 eine Erhöhung des bedingten Kapitals gemäss näherer Umschreibung in den Statuten beschlossen. Änderung des Kapitalbands gemäss näherer Umschreibung in den Statuten.

    Ausgeschiedene Personen und erloschene Unterschriften:
    Ropponen, Henni-Karoliina, finnische Staatsangehörige, in Röschenz, Mitglied des Verwaltungsrates, mit Kollektivunterschrift zu zweien.

    Eingetragene Personen neu oder mutierend:
    Schulze, Ulrik, von Zumikon, in Zumikon, Mitglied des Verwaltungsrates, ohne Zeichnungsberechtigung.

    SHAB 250603/2025 - 03.06.2025
    Kategorien: Diverse Änderungen

    Publikationsnummer: UP04-0000007270, Handelsregister-Amt Zürich

    "Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 03.06.2025/nPublicly viewable until: 03.06.2026/nPublication number: UP04-0000007270/nPublishing entity/nHomburger AG, Hardstrasse 201.

    8005 Zürich/nInvitation to the ordinary general meeting/nBioVersys AG/nOrganisation concerned:
    /nBioVersys AG/nCHE-114.512.761/nHochbergerstr. 60C/n4057 Basel/nGeneral meeting details:/n27.06.2025, 12.00 Uhr.

    ZIP Auditorium Stückipark/nHochbergerstrasse 60F/n4057 Basel/nInvitation/Agenda:
    /nInvitation to the Annual General Meeting of BioVersys AG. The full text of the invitation is/nincluded in the attached PDF./n1/11/nInvitation/nto the Annual General Meeting of BioVersys AG/nDay: Friday, June 27.

    2025/nTime:
    12 pm CEST (doors open 11.30 am CEST)/nPlace: ZIP Auditorium Stückipark, Hochbergerstrasse 60F, 4057 Basel/n2/11/nAgenda and Proposals of the Board of Directors/n1. Annual Report 2024 (Annual Financial Statements and Consolidated Financial/n Statements 2024;
    Auditor's Reports)/n The Board of Directors proposes that the annual financial statements and the consolidated fi-/n nancial statements 2024 be approved and that the Auditors' reports be acknowledged./n Explanation: In accordance with article 698 paragraph 2 items 3 and 4 of the Swiss Code of Ob-/n ligations (CO) and the Articles of Association, the Annual General Meeting is responsible for ap-/n proving the annual financial statements and the consolidated financial statements./n2. Discharge of the Members of the Board of Directors and the Executive Committee from/n Liability/n The Board of Directors recommends that the members of the Board of Directors and the Execu-/n tive Committee be granted discharge for their activities in the financial year 2024./n Explanation: In accordance with article 698 paragraph 2 item 7 CO and the Articles of Associa-/n tion, the Annual General Meeting is responsible for granting discharge to the members of the/n Board of Directors and the Executive Committee./n3. Appropriation of Financial Result 2024/n The Board of Directors proposes that the accumulated loss of the Company in the amount of/n CHF 79,936 thousand be allocated as follows:/n Loss of the financial year 2024 CHF (14,373 thousand)/n Loss carried forward from previous year CHF (65,563 thousand)/n Balance to be carried forward CHF (79,936 thousand)/n Explanation: In accordance with article 698 paragraph 2 item 4 CO and the Articles of Associa-/n tion, the Annual General Meeting is responsible for passing resolutions on the appropriation of/n the balance sheet profit, allocation of reserves and the payment of a dividend./n 3/11/n4. Elections and/or Re-elections/n4.1 Election/Re-election of the Chairman and the Members of the Board of Directors/n Dr. Seng Chin Mah is standing for and has declared acceptance of his re-election as Chairman/n of the Board of Directors for a term of office until the completion of the next Annual General/n Meeting./n The following current members of the Board of Directors, Dr. David Hunstad, Dr. Marc Gitz-/n inger, Ms. Marina von Schönau and Dr. William Jenkins, are also standing and have declared/n acceptance of their re-election as members of the Board of Directors for a term of office until the/n completion of the next Annual General Meeting./n Dr. Henni-Karoliina Ropponen will not stand for re-election as a member of the Board of Directors./n We thank her for her invaluable contributions to the Board of Directors as well as her efforts/n towards the IPO./n The Board of Directors proposes to elect Dr. Ulrik Schulze as a new member of the Board of Di-/n rectors./n The Board of Directors proposes to re-elect the following members of the Board of Directors,/n and to elect the following new candidate as a member of the Board of Directors, individually and/n for a term of office lasting until the completion of the next Annual General Meeting./n Explanation: Pursuant to article 698 paragraph 2 item 2 and paragraph 3 item 1 CO and the Ar-/n ticles of Association, the Annual General Meeting is responsible for the following elections of the/n Chairman and the members of the Board of Directors. The Board of Directors and the Compen-/n sation and Nomination Committee are convinced that the persons proposed for election and re-/n election, respectively, have the necessary qualifications to serve on the Board of Directors of/n BioVersys./n For biographical details on the candidates to be re-elected, please refer to the company's web-/n site (https://www.bioversys.com/about-us/board-of-directors/)./n Dr. Ulrik Schulze is a senior partner & managing director at The Boston Consulting Group (BCG)./n He led BCG's global biopharma sector for many years and held leadership positions in BCG/n Switzerland, including Head of Business Development, People Chair, and Head of the Health/n Care business. Dr. Schulze has more than 30 years of experience in the life science industry/n working with boards, CEOs, and senior executives in Europe, the US, and Asia. His work has/n focused on strategy development, capital markets, M&A, post-merger integration, and organiza-/n tional transformations across the value chain. In 2022, he co-authored the report ""The case for a/n subscription model to tackle antimicrobial resistance"". He is also a co-founder of ReproNovo SA,/n a biotech company in reproductive medicine, that has raised USD 65 million in Series A funding/n and Sanrigen GmbH, a life science advisory firm. Dr. Schulze is Swiss, born in 1967 and holds a/n doctorate degree in Biotechnology from the Technical University of Denmark./n 4/11/n4.1.1 Re-election of Seng Chin Mah as Chairman of the Board of Directors/n4.1.2 Re-election of David Hunstad as Member of the Board of Directors/n4.1.3 Re-election of Marc Gitzinger as Member of the Board of Directors/n4.1.4 Re-election of Marina von Schönau as Member of the Board of Directors/n4.1.5 Re-election of William Jenkins as Member of the Board of Directors/n4.1.6 Election of Ulrik Schulze as Member of the Board of Directors/n4.2 Re-election of the Members of the Compensation and Nomination Committee/n The current members of the Compensation and Nomination Committee, Dr. Seng Chin Mah,/n Dr. David Hunstad and Ms. Marina von Schönau, have declared acceptance of their re-election/n as members of the Compensation and Nomination Committee for a term of office until the com-/n pletion of the next Annual General Meeting, subject to their re-election as Chairman or member/n of the Board of Directors, respectively. The Board of Directors proposes to re-elect the following/n members of the Compensation and Nomination Committee individually and for a term of office/n lasting until the completion of the next Annual General Meeting./n4.2.1 Re-election of Seng Chin Mah as Member of the Compensation and Nomination/n Committee/n4.2.2 Re-election of David Hunstad as Member of the Compensation and Nomination/n Committee/n4.2.3 Re-election of Marina von Schönau as Member of the Compensation and Nomination/n Committee/n Explanation: Pursuant to article 698 paragraph 3 item 2 CO and the Articles of Association, the/n Annual General Meeting is responsible for the election of the members of the Nomination & Re-/n muneration Committee. The Board of Directors and the Nomination & Remuneration Committee/n are convinced that the persons proposed for re-election have the necessary qualifications to/n serve on the Nomination & Remuneration Committee./n 5/11/n4.3 Election of the Independent Voting Rights Representative/n The Board of Directors proposes to elect Lenz Caemmerer, Attorneys at Law & Notaries, Elisa-/n bethenstrasse 15, 4010 Basel as Independent Voting Rights Representative for a term of office/n until the completion of the next Annual General Meetin"

    SHAB 250319/2025 - 19.03.2025
    Kategorien: Änderung am Kapital

    Publikationsnummer: HR02-1006286040, Handelsregister-Amt Basel-Stadt, (270)

    BioVersys AG, in Basel, CHE-114.512.761, Aktiengesellschaft (SHAB Nr. 27 vom 10.02.2025, Publ. 1006252149).

    Statutenänderung:
    17.03.2025.

    Aktienkapital neu:
    CHF 5'823'480.00 [bisher: CHF 5'775'618.00].

    Liberierung Aktienkapital neu:
    CHF 5'823'480.00 [bisher: CHF 5'775'618.00].

    Aktien neu:
    5'823'480 Namenaktien zu CHF 1.00 [bisher: 5'775'618 Namenaktien zu CHF 1.00]. Ordentliche Kapitalerhöhung innerhalb Kapitalband.

    Trefferliste

    Hier finden Sie eine Verlinkung des Managements auf eine Trefferliste zu Personen mit dem gleichen Namen, die im Handelsregister eingetragen sind.

    Title
    Bestätigen